Steven Cohn

View Scopus Profile

Emailsmcohnutmbedu

h-index

Research activity per year

If you made any changes in Pure these will be visible here soon.

Research Strategic Pillar Keywords

Specialized Health

Fingerprint

Dive into the research topics where Steven Cohn is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

1 Similar Profiles

6 Active
8 Completed

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
Eli Lilly & Company
5/13/20 → 5/12/25
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
Eli Lilly & Company
5/13/20 → 5/12/25
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
5/13/20 → 5/12/25
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.
Cohn, S.
Eli Lilly
2/27/20 → 2/26/25
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.
Cohn, S.
2/27/20 → 2/26/25
Project: Other project

42 Article
2 Chapter
1 Review article

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production
Yang, W., Liu, H., Xu, L., Yu, T., Zhao, X., Yao, S., Zhao, Q., Barnes, S., Cohn, S. M., Dann, S. M., Zhang, H., Zuo, X., Li, Y. & Cong, Y., Jan 2022, In: Gastroenterology. 162, 1, p. 150-165 16 p.
Research output: Contribution to journal › Article › peer-review

Open Access
13 Scopus citations
AIDS-associated Esophageal Plasmablastic Lymphoma
Abdulla, H. M. & Cohn, S., Jan 2021, In: Clinical Gastroenterology and Hepatology. 19, 1, p. A18
Research output: Contribution to journal › Article › peer-review

1 Scopus citations
Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception
Nguyen, C., Kline, K. T., Merwat, S. N., Merwat, S., Luthra, G., Parupudi, S. & Cohn, S., Dec 2021, In: BMC Gastroenterology. 21, 1, 344.
Research output: Contribution to journal › Article › peer-review

Open Access
Patients with gastric antral vascular ectasia (Gave) are at a higher risk of gastrointestinal bleeding in the absence of cirrhosis
Wang, J., Stine, J. G., Cornella, S. L., Argo, C. K. & Cohn, S. M., 2015, In: Journal of Clinical and Translational Hepatology. 3, 4, p. 254-259 6 p.
Research output: Contribution to journal › Article › peer-review

Open Access
10 Scopus citations
Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways
Brodrick, B., Vidrich, A., Porter, E., Bradley, L., Buzan, J. M. & Cohn, S. M., May 27 2011, In: Journal of Biological Chemistry. 286, 21, p. 18515-18525 11 p.
Research output: Contribution to journal › Article › peer-review

Open Access
17 Scopus citations

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Dive into details

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

GPR120 Inhibits Colitis Through Regulation of CD4⁺ T Cell Interleukin 10 Production

AIDS-associated Esophageal Plasmablastic Lymphoma

Restarting elective endoscopy safely amidst an evolving pandemic and the impact of patient perception

Patients with gastric antral vascular ectasia (Gave) are at a higher risk of gastrointestinal bleeding in the absence of cirrhosis

Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways

Steven Cohn, MD, PhD, AGAF, FACG

Personal profile

Research Strategic Pillar Keywords

Fingerprint

Network

Projects

Research output